RxDoctor Payments Data

Taylor Kelly

Physician Assistant · Fort Worth, TXNPI 1720768534

Payments from drug & device makers

$6,628in general payments, 2019–2025

Across 182 payments — averaging $36.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • E.r. Squibb & Sons, L.L.C.$597
  • Merck$593
  • Novartis$464
  • Pfizer$383
  • AstraZeneca$370
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$1,15617%
  • Food & beverage$5,47283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,628 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$34,941
Medicare patients
323
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$181,707
EntrestoSacubitril/Valsartan61$63,976
XareltoRivaroxaban46$63,011
Repatha SureclickEvolocumab13$14,721
MultaqDronedarone Hcl14$13,061
FarxigaDapagliflozin Propanediol12$9,749
Ranolazine ErRanolazine66$6,320
Enoxaparin Sodium11$4,376
Metoprolol Succinate131$1,531
Clonidine13$1,133
Flecainide Acetate25$771
ClopidogrelClopidogrel Bisulfate56$692
Nitroglycerin64$681
Amlodipine Besylate98$643
Rosuvastatin Calcium60$569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$383$181,707145 claims
NovartisEntresto$464$63,97661 claims
Johnson & JohnsonXarelto$55$63,01146 claims
Sanofi-aventis U.S. LLCMultaq$20$13,06114 claims
AstraZenecaFarxiga$370$9,74912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →